Skip to main content
. 2023 Dec 15;24:100902. doi: 10.1016/j.mtbio.2023.100902

Fig. 4.

Fig. 4

(a) Cell viability experiment of SMMC7721 and SMMC7721/S cells incubated by various concentrations of sorafenib. (n = 4, mean ± SD). (b) Relative cell viability of different treatments for SMMC7721/S cells. (n = 4, mean ± SD). (c, d) Flow cytometric analysis on the apoptosis levels of SMMC7721/S cells after different treatments (Control, Ce6 + laser, sorafenib, MCS NPs, and MCS NPs + laser). (n = 3, mean ± SD). (Control: no drugs added during the cultivation process, Ce6+: Ce6 with 660 nm laser irradiation, Sorafenib: sorafenib without laser irradiation, NPs: MCS NPs without laser irradiation, NPs+: MCS NPs with laser irradiation). (e, f) Western blotting showed the HIF-1α expression levels after treatment with Ce6 + laser, sorafenib, MCS NPs, and MCS NPs + laser for 24 h (n = 3, mean ± SD). (g) ROS generation of SMMC7721/S cells. Scale bar: 50 μm. (h) Quantitative fluorescence intensity of ROS by different treatments. (n = 3, mean ± SD). **P < 0.01, ***P < 0.001, t-test. Ce6 (5.26 μg/mL), sorafenib (4.05 μg/mL), MCS NPs (Ce6: 5.26 μg/mL, sorafenib: 4.05 μg/mL).